FindTrial
Sign In

An Adaptive Clinical Platform Trial to Evaluate the Safety and Efficacy of COM701 as Monotherapy or Combination Therapy as Maintenance Therapy in Participants with Relapsed Platinum Sensitive Ovarian Cancer (PSOC)

Status
Recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-521125-33-00
Acronym
CPG-01-201
Enrollment
20
Registered
2025-07-29
Start date
2025-09-05
Completion date
Unknown
Last updated
2025-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer, Recurrent Ovarian Cancer

Brief summary

Progression free survival per investigator assessed RECIST 1.1 in COM701-treated participants compared to placebo-treated participants

Detailed description

Frequency of AEs and SAEs and severity per CTCAE 5.0 in COM701-treated participants compared to placebo-treated participants, Changes from baseline in safety laboratory parameters, vital signs and ECG in COM701-treated participants compared to placebo-treated participants., Time to the initiation of a new anti-cancer treatment in COM701-treated participants compared to placebo-treated participants

Interventions

DRUGSALINE

Sponsors

Compugen Ltd., Compugen Ltd.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Progression free survival per investigator assessed RECIST 1.1 in COM701-treated participants compared to placebo-treated participants—

Secondary

MeasureTime frame
Frequency of AEs and SAEs and severity per CTCAE 5.0 in COM701-treated participants compared to placebo-treated participants, Changes from baseline in safety laboratory parameters, vital signs and ECG in COM701-treated participants compared to placebo-treated participants., Time to the initiation of a new anti-cancer treatment in COM701-treated participants compared to placebo-treated participants—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026